The company's EPS and revenue growth don't match its share price decline, hinting at possible over-hype or other factors. Last year's performance suggests unresolved issues. Investors should consider financial health and potential risks before investing.
The company's P/E ratio aligns with moderate growth expectations, yet the market is predicted to grow by 16% annually, a more appealing prospect. Investors holding onto their stock may face future disappointment if the P/E aligns with the growth outlook.
The company's consistent reinvestment of capital at increasing rates of return is promising. Despite the stock's past decline, ongoing trends may offer investment opportunities. Further research into the company and its future trends is advised.
Despite appearing high, the P/E ratio's justification is debatable. With subpar growth estimates compared to the market, its sustainability is uncertain, posing significant risks for current shareholders and potential overpayment for novices.
While offloading of shares by insiders could raise concerns, the comparatively high selling price relative to the current price offers some comfort. However, there have been no recent insider transactions, which could be a less encouraging sign for potential investors.
Shandong Weigao Group's dividends are considered sustainable given their coverage by profits and cash flow. The company's potential for more dividend increases is indicated by its reasonable payout ratio and earnings growth. Analysts commend its consistent earnings growth and efficient cash flow use.
威高股份(ADR)股票討論區
DBS: China Healthcare Sector – Pharmaceutical Packaging
$微創醫療(00853.HK)$$威高股份(01066.HK)$$石藥集團(01093.HK)$$國藥控股(01099.HK)$$華潤醫療(01515.HK)$$康臣葯業(01681.HK)$$春立醫療(01858.HK)$$環球醫療(02666.HK)$$復宏漢霖(02696.HK)$$創業慧康(300451.SZ)$$柳藥集團(603368.SH)$$百濟神州(06160.HK)$
DBS: Shandong Weigao Group Medical Polymer Co Ltd – Buy Target Price HK$14.50
$威高股份(01066.HK)$
DBS: China Biotech Sector
$百濟神州(06160.HK)$$石藥集團(01093.HK)$$復宏漢霖(02696.HK)$$微創醫療(00853.HK)$$威高股份(01066.HK)$$國藥控股(01099.HK)$$華潤醫療(01515.HK)$$康臣葯業(01681.HK)$$春立醫療(01858.HK)$$環球醫療(02666.HK)$$復宏漢霖(02696.HK)$$創業慧康(300451.SZ)$$柳藥集團(603368.SH)$$百濟神州(06160.HK)$
暫無評論